Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antitumorigenic actions of growth hormone-releasing hormone antagonists.

× No keyword cloud information.

30 in total

Review 1. cAMP-dependent protein kinase: role in normal and malignant growth.

Authors: Y S Cho-Chung; S Pepe; T Clair; A Budillon; M Nesterova
Journal: Crit Rev Oncol Hematol Date: 1995-11 Impact factor: 6.312

Review 2. A critical view of the methods for characterization of the VIP/PACAP receptor subclasses.

Authors: P Robberecht; M Waelbroeck
Journal: Ann N Y Acad Sci Date: 1998-12-11 Impact factor: 5.691

3. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.

Authors: J M Chan; M J Stampfer; E Giovannucci; P H Gann; J Ma; P Wilkinson; C H Hennekens; M Pollak
Journal: Science Date: 1998-01-23 Impact factor: 47.728

4. Antagonistic analogs of growth hormone releasing hormone (GHRH) inhibit cyclic AMP production of human cancer cell lines in vitro.

Authors: V Csernus; A V Schally; K Groot
Journal: Peptides Date: 1999 Impact factor: 3.750

5. Inhibition of growth of human small cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH).

Authors: J Pinski; A Schally; A Jungwirth; K Groot; G Halmos; P Armatis; M Zarandi; M Vadillobuenfil
Journal: Int J Oncol Date: 1996-12 Impact factor: 5.650

6. Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo.

Authors: K Maruno; A Absood; S I Said
Journal: Proc Natl Acad Sci U S A Date: 1998-11-24 Impact factor: 11.205

7. Induction of phenotypic changes in SCLC cell lines in vitro by hexamethylene bisacetamide, sodium butyrate, and cyclic AMP.

Authors: M Z Khan; R I Freshney; A M McNicol; A M Murray
Journal: Ann Oncol Date: 1993-06 Impact factor: 32.976

8. Retinoic acid down-regulates the expression of the vasoactive intestinal polypeptide receptor type-1 in human breast carcinoma cell lines.

Authors: B Madsen; B Georg; H Vissing; J Fahrenkrug
Journal: Cancer Res Date: 1998-11-01 Impact factor: 12.701

9. Metastatic behavior of the RIF-1 murine fibrosarcoma: inhibited by hypophysectomy and partially restored by growth hormone replacement.

Authors: A Sekyi-Otu; R Bell; I Andrulis; M Pollak
Journal: J Natl Cancer Inst Date: 1994-04-20 Impact factor: 13.506

10. Cyclic-AMP-stimulated synthesis and release of carcinoembryonic antigen by pancreatic cancer cells.

Authors: T L Sack; J R Gum; Y S Kim
Journal: Int J Pancreatol Date: 1988-03

12 in total

1. The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues.

Authors: Alexandre Havt; Andrew V Schally; Gabor Halmos; Jozsef L Varga; Gabor L Toller; Judit E Horvath; Karoly Szepeshazi; Frank Köster; Kevin Kovitz; Kate Groot; Marta Zarandi; Celia A Kanashiro
Journal: Proc Natl Acad Sci U S A Date: 2005-11-18 Impact factor: 11.205

Review 2. Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies.

Authors: Megan C Chapter; Caitlin M White; Angela DeRidder; Wayne Chadwick; Bronwen Martin; Stuart Maudsley
Journal: Pharmacol Ther Date: 2009-08-15 Impact factor: 12.310

3. Antagonist of growth hormone-releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway.

Authors: Zoltan Rekasi; Tamas Czompoly; Andrew V Schally; Ferenc Boldizsar; Jozsef L Varga; Marta Zarandi; Timea Berki; Reka A Horvath; Peter Nemeth
Journal: Proc Natl Acad Sci U S A Date: 2005-02-22 Impact factor: 11.205

4. Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor.

Authors: Nektarios Barabutis; Erasmia Tsellou; Andrew V Schally; Stavroula Kouloheri; Anastasios Kalofoutis; Hippokratis Kiaris
Journal: Proc Natl Acad Sci U S A Date: 2007-03-19 Impact factor: 11.205

5. Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel.

Authors: Florian Hohla; Andrew V Schally; Karoly Szepeshazi; Jozsef L Varga; Stefan Buchholz; Frank Köster; Elmar Heinrich; Gabor Halmos; Ferenc G Rick; Chandrika Kannadka; Christian Datz; Celia A Kanashiro
Journal: Proc Natl Acad Sci U S A Date: 2006-09-18 Impact factor: 11.205

6. Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers.

Authors: Z Rekasi; T Czompoly; A V Schally; G Halmos
Journal: Proc Natl Acad Sci U S A Date: 2000-09-12 Impact factor: 11.205

7. Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone.

Authors: G Halmos; A V Schally; J L Varga; A Plonowski; Z Rekasi; T Czompoly
Journal: Proc Natl Acad Sci U S A Date: 2000-09-12 Impact factor: 11.205

8. Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone.

Authors: Gunhild Keller; Andrew V Schally; Kate Groot; Gabor L Toller; Alexandre Havt; Frank Köster; Patricia Armatis; Gabor Halmos; Marta Zarandi; Jozsef L Varga; Jörg B Engel
Journal: Proc Natl Acad Sci U S A Date: 2005-07-18 Impact factor: 11.205

9. Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs.

Authors: Hippokratis Kiaris; Andrew V Schally; Rebeca Busto; Gabor Halmos; Spyros Artavanis-Tsakonas; Jozsef L Varga
Journal: Proc Natl Acad Sci U S A Date: 2002-01-02 Impact factor: 11.205

10. The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas.

Authors: Rebeca Busto; Andrew V Schally; Jozsef L Varga; M Olga Garcia-Fernandez; Kate Groot; Patricia Armatis; Karoly Szepeshazi
Journal: Proc Natl Acad Sci U S A Date: 2002-08-19 Impact factor: 11.205